Loading
A phase 2 trial of Anlotinib in sarcomas, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma is a phase 2 interventional study registered as NCT07548177 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 33 participants planned, started 2026-04-02 and due to reach its primary completion in 2027-11. Interventions recorded: Benmelstobart injection combined with Anlotinib hydrochloride capsule.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Anlotinib, Sino Biopharmaceutical (Chia Tai Tianqing), Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Benmelstobart and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/